FDA Approval Alert: The Need-to-Know | Pirtobrutinib for Relapsed/Refractory MCL

In January 2023, the FDA gave accelerated approval to pirtobrutinib for the treatment of patients with relapsed/refractory mantle cell lymphoma following at least 2 prior lines of therapy.

The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.
FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed/Refractory MCL
Article
Jan 27, 2023 9:23 PM
The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.